Estudo randomizado | Riociguate melhorou a hemodinâmica, mas aumentou intolerância na hipertensão pulmonar e insuficiência cardíaca com fração de ejeção preservada (HFpEF – heart failure with preserved ejection fraction).
17 Out, 2022 | 12:42h
Comentário no Twitter
Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: results of randomized, double-blind, placebo-controlled, multicentre trial out.https://t.co/FYmorikQR5#HFpEF #HF #cardiotwitter @ESC_Journals @escardio pic.twitter.com/4sSeYt7Adq
— EHJ Editor-in-Chief (@ehj_ed) October 7, 2022
Sob licenca de https://creativecommons.org/licenses/by-nc/4.0/